Search Bar & Filters
Found 20 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.
Actively Recruiting
Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.
Actively Recruiting
Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the impact of the Cost Communication and Financial Navigation CostCOM intervention on adherence to cancer care and financial burden among patients with malignant solid tumors. This study compares the effects of enhanced usual care and the CostCOM program, which offers financial counseling and resource connections to reduce financial barriers and stress. The study aims to assess cost-related non-adherence, financial hardship, worry, quality of life, and satisfaction with care over 12 months. Participants are randomly assigned to one of two groups one group receives a brochure about financial navigation services, while the other group receives usual financial care plus CostCOM counseling sessions lasting about one hour within 30 days of enrollment and again at 3, 6, and 12 months. Non-patient participants involved in the study complete surveys and participate in in-depth interviews between 15 and 39 months after the first patient enrollment. During the study, patients complete surveys at baseline and at 3, 6, and 12 months to report on financial worry, quality of life, and satisfaction with care. Researchers track adherence to cancer treatment and financial outcomes over one year. Non-patient participants contribute by completing surveys and interviews to provide insights into the use and experience of the CostCOM intervention. The total participation time extends up to 12 months for patients and up to 39 months for non-patient participants.
Actively Recruiting
Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.
Actively Recruiting
Researchers are evaluating a new device called the Helioscope, developed by Cassini Technologies B.V., which combines LED-based corneal topography with swept-source optical coherence tomography SS-OCT to quickly and accurately measure the shape of the cornea and other eye structures. This next-generation optical biometer is designed to provide measurements even in eyes with dense cataracts, which can affect optical properties and measurement accuracy. The study aims to collect data from eyes with cataracts to help improve the devices software algorithms. Participants will have their eye measurements taken in a single visit using three devices the investigational Helioscope optical biometer, and two FDA-cleared comparator devicesthe Cassini Ambient corneal topographer and the Argos optical biometer. These measurements will be compared to evaluate the accuracy and agreement of the new device. There is no treatment or intervention assignment as part of this study it focuses solely on diagnostic comparison. During the study visit, participants will undergo ocular biometry to measure parameters such as axial length, keratometry, anterior chamber depth, lens thickness, and total corneal astigmatism using all three devices. Researchers will monitor the measurements over a period of up to 12 months to assess the Helioscopes performance in cataractous eyes. Safety is ensured by selecting participants able to provide informed consent and properly fixate during measurements.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.
Actively Recruiting
This research aims to better understand cancer cachexia CC, a condition involving weight, muscle, and fat loss that affects patients with advanced colorectal, lung, or pancreatic cancer that cannot be removed by surgery or is at stage IV. CC is linked to reduced physical function, lower quality of life, and poorer survival. The study seeks to identify different subtypes of CC based on patient characteristics to improve diagnosis and tailor treatments more effectively than a one-size-fits-all approach. It also aims to validate these subtypes and explore tumor factors that may contribute to CC. Participants will complete surveys and physical function tests lasting about 30 minutes each, provide blood samples and archived tumor tissue, and wear an actigraph device for 7 days to monitor sleep and activity. These assessments occur at the start of the study and again after three months. Standard imaging scans such as CT or PETCT are performed as part of usual care throughout the study. Medical records are reviewed at baseline, 3 months, and 1 year to collect comprehensive clinical data. During the study, researchers will evaluate physical function, symptoms, body composition, blood biomarkers, and activity levels to identify distinct CC diagnostic subtypes and their association with survival. Surveys and functional tests help measure symptoms and physical ability. The actigraph tracks daily activity and sleep patterns. The study follows participants for up to one year to monitor changes and outcomes, aiming to build a detailed database to support future research and clinical trials for cancer-related weight and muscle loss.
1-10 of 20
1